Crizotinib in ROS1-rearranged non-small-cell lung cancer.
New England Journal of Medicine.
Times cited: 905
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: A multicentre, open-label, phase 2 trial.
The Lancet Oncology.
Times cited: 80